Surgical Treatment of Concurrent Cataract & Primary Pterygium

Status Recruiting

Clinical Trial Summary

Pterygium is known to induce with-the-rule astigmatism. The corneal curvature along the long axis of the pterygium body is flattened. The excision of pterygium will result in steepening of the cornea and reduction of astigmatism. Therefore, the effect of pterygium excision on intraocular lens (IOL) power calculation has been examined in our previous study. The study confirmed that pterygium can cause alteration of IOL power.

The determination of IOL power for cataract surgery is usually calculated from IOL formula called SRK II formula. IOL power = A - (2.5 x AL)-(0.9 x K). Variable A denotes the A-constant of the intraocular lens which is dependent on the IOL material and refractive index. Other variables for input include axial length (AL) and keratometry (K). A larger K reading will result in a lower estimated IOL power and vice versa. Previous studies have documented simultaneous cataract and pterygium operation resulted in reasonable visual outcome without adjustment of IOL power.

With the presence of a pterygium, the cornea is flattened and lead to a reduction of K value and over-estimation of calculated IOL power. This randomized controlled trial is designed to compare the refractive outcomes of sequential and simultaneous pterygium and cataract operation.

Pterygium excision should be done with various adjuvant therapies to minimize recurrence. Our previous studies reliably demonstrated limbal conjunctival graft and mitomycin C were effective methods to achieve low pterygium recurrence. We use limbal conjunctival autograft as the adjuvant therapy in the current study because this method is safer to be performed either alone or in combination with phacoemulsification. We avoid using mitomycin C as the adjuvant therapy in order to minimize the possibility of intraocular toxicity due to seepage.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00563277
Study type	Interventional
Source	Hospital Authority, Hong Kong
Contact	Lulu Cheng, Dr
Phone	(852) 2632 2878
Email	chenglu@i-cable.com
Status	Recruiting
Phase	N/A
Start date	October 2004
Completion date	December 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04685538` - Chloroprocaine 3% Gel Eye Drop as Topical Anestheticsin Phacoemulsification.	Phase 3
Recruiting	`NCT06060041` - IC-8 Apthera IOL New Enrollment Post Approval Study
Recruiting	`NCT05518539` - Evaluation of Quality of Vision and Visual Outcomes With Bilateral Implantation of the Clareon PanOptix Intraocular Lens
Recruiting	`NCT05271942` - Tilt and Tumble vs Divide and Conquer - a Unique Comparison of the Two Cataract Surgery Methods	N/A
Active, not recruiting	`NCT04778501` - PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia	N/A
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT03751033` - Influence of DisCoVisc Ophthalmic Viscosurgical Device (OVD) on Intraoperative Aberrometry Readings	N/A
Completed	`NCT02529488` - Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00	N/A
Completed	`NCT04539548` - A Study Assessing the Safety and Efficacy of Dextenza® for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract	Phase 3
Completed	`NCT03740659` - Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery	Phase 2
Completed	`NCT03494257` - Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification	N/A
Completed	`NCT05119127` - Rotational Stability of Acrysof IQ Vivity Extended Vision Toric IOL and Refractive Visual Outcome.	N/A
Active, not recruiting	`NCT04271709` - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)	N/A
Recruiting	`NCT03713268` - Intraoperative OCT Guidance of Intraocular Surgery II
Completed	`NCT03739528` - Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery	Phase 3
Completed	`NCT02888210` - A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery	Phase 3
Completed	`NCT03356847` - Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery	N/A
Completed	`NCT04332640` - Clinical Evaluation of the Next Generation Phaco System	N/A
Recruiting	`NCT03638726` - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification	Phase 4
Completed	`NCT03050697` - Evaluation of the Safety and Performance of the HARMONI® Toric Lens	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Surgical Treatment of Concurrent Cataract and Primary Pterygium

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms